Navigation Links
Jacobs Receives Contract From Gedeon Richter for New Biotechnology Facility in Hungary
Date:9/30/2008

PASADENA, Calif., Sept. 30 /PRNewswire-FirstCall/ -- Jacobs Engineering Group Inc. (NYSE: JEC) announced today that it received a contract from Gedeon Richter (BSE: GDRB) to provide engineering, procurement, and construction management services and validation assistance for a grassroots, multi-purpose biotechnology research & development and manufacturing facility in Debrecen, Hungary.

Officials did not disclose contract details but noted they would execute the work from their office in Milan, Italy.

Gedeon Richter, headquartered in Budapest, Hungary, is one of the largest multinational pharmaceutical companies in Central Eastern Europe and the Commonwealth of Independent States. It has a growing presence through commercial subsidiaries in key European Union countries, Asia, and the United States.

In making the announcement, Jacobs Group Vice President Robert Matha said "We are eager to help Gedeon Richter with this important project, which strengthens its commitment to biotechnology. In supporting the company's strategic goal of establishing a strong biopharma line, we also help Gedeon Richter to expand its worldwide portfolio of high value products."

Jacobs, with over 56,000 employees and revenues exceeding $10.0 billion, provides technical, professional, and construction services globally.

Any statements made in this release that are not based on historical fact are forward-looking statements. Although such statements are based on management's current estimates and expectations, and currently available competitive, financial, and economic data, forward-looking statements are inherently uncertain. We, therefore, caution the reader that there are a variety of factors that could cause business conditions and results to differ materially from what is contained in our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our 2007 Form 10-K, and in particular the discussions contained under Items 1 - Business, 1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We also caution the readers of this release that we do not undertake to update any forward-looking statements made herein.

For additional information contact:

Michelle Jones

626.578.6968

(Logo: http://www.newscom.com/cgi-bin/prnh/20051021/LAJACOBSEGLOGO)


'/>"/>
SOURCE Jacobs Engineering Group Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
2. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
3. Kuvan Receives Positive Opinion From CHMP for European Approval
4. Corgenix Receives Third U.S. Patent on AtherOx(R) Technology
5. Sustainable Oils Receives Regulatory Approval for Feeding Camelina Meal in Livestock Diets
6. U.S. Genomics Inc. Receives $4.5 Million Investment from BD
7. AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM)
8. PLC Systems Receives Delisting Notice From American Stock Exchange
9. Nephros Receives Non-Compliance Notification from AMEX
10. China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII
11. Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... method to engineer scalable and customizable vascular grafts in JoVE’s Video Journal, the ... lead to new and improved ways of treating coronary artery disease (CAD). Lam ...
(Date:3/24/2017)... , March 24, 2017  Infectex Ltd., a ... today announced positive results of a Phase 2b-3 clinical ... regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 ... at Sequella, Inc. ( USA ) and ... A total of 140 patients were enrolled in a ...
(Date:3/24/2017)... Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company ... vaccines, today announced participation at the following conferences: ... and Maidstone Life Sciences conference "Cancer Immunotherapy Conference" at ... New York, NY . Agenus will participate in ... am: Robert B. Stein , M.D., Ph.D., President, ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseq™ Inherited Cancer DNA ... from industry experts to validate the ability ...
Breaking Biology Technology:
(Date:3/6/2017)... March 6, 2017 Mintigo , ... today announced Predictive Sales Coach TM , its ... sales intelligence into Salesforce. This unique AI application ... sales organizations with deep knowledge of their customers ... intelligent engagement. Predictive Sales Coach extends Mintigo,s existing ...
(Date:3/2/2017)... -- Summary This report provides all the ... its partnering interests and activities since 2010. Download ... Partnering Deals and Alliance since 2010 report provides an ... the world,s leading life sciences companies. On ... inclusion of the most up to date deal and ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
Breaking Biology News(10 mins):